# OnCo record veru (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/veru/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "veru" ;
  schema:name "Veru"@en ;
  schema:alternateName "Veru Inc."@en, "Veru Pharma"@en ;
  schema:description "Veru is a Miami company whose oncology programmes were the selective androgen receptor modulator enobosarm for AR-positive, ER-positive breast cancer and the microtubule disruptor sabizabulin for prostate cancer, which was halted in 2022."@en ;
  schema:url <https://onco.cc/companies/veru/>, <https://verupharma.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://verupharma.com>, <https://clinicaltrials.gov/search?lead=Veru>, <https://en.wikipedia.org/wiki/Veru_Inc.> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/prostate/> ;
  onco:sections <https://onco.cc/fronts/hormonal/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/> .